These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22551924)

  • 41. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
    Printz C
    Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
    Santarpia M; Altavilla G; Pitini V; Rosell R
    Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.
    Galetta D; Rossi A; Pisconti S; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S45-54. PubMed ID: 22443113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. For EGFR research, new targeted drugs mean new questions.
    Vastag B
    J Natl Cancer Inst; 2005 May; 97(9):628-30. PubMed ID: 15870431
    [No Abstract]   [Full Text] [Related]  

  • 47. Molecular markers for incidence, prognosis, and response to therapy.
    Tong BC; Harpole DH
    Surg Oncol Clin N Am; 2012 Jan; 21(1):161-75. PubMed ID: 22098838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting resistance in lung cancer.
    Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
    [No Abstract]   [Full Text] [Related]  

  • 49. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
    Gille J
    Exp Dermatol; 2006 Mar; 15(3):175-86. PubMed ID: 16480425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.
    Felip E; Martinez-Marti A; Martinez P; Cedres S; Navarro A
    Curr Opin Oncol; 2013 Mar; 25(2):115-20. PubMed ID: 23262832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New targets and new mechanisms in lung cancer.
    Carrizosa DR; Mileham KF; Haggstrom DE
    Oncology (Williston Park); 2013 May; 27(5):396-404. PubMed ID: 25184262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 53. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.
    Capelletto E; Novello S; Scagliotti GV
    Future Oncol; 2014 May; 10(6):1081-93. PubMed ID: 24941991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted treatments in colorectal cancer: state of the art and future perspectives.
    Arnold D; Seufferlein T
    Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Targeted therapies in hepatocellular carcinomas: recent results and future development].
    Marijon H; Faivre S; Raymond E
    Bull Cancer; 2009 May; 96(5):553-61. PubMed ID: 19467986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New and emerging targeted treatments in advanced non-small-cell lung cancer.
    Hirsch FR; Suda K; Wiens J; Bunn PA
    Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.
    Gori B; Ricciardi S; Fulvi A; Del Signore E; de Marinis F
    Future Oncol; 2012 May; 8(5):559-73. PubMed ID: 22646771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement in lung cancer outcomes with targeted therapies: an update for family physicians.
    Rolfo C; Passiglia F; Ostrowski M; Farracho L; Ondøichová T; Dolcan A; Castiglia M; Remmen R; Papadimitriou K; Pauwels P
    J Am Board Fam Med; 2015; 28(1):124-33. PubMed ID: 25567833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New targets and new drugs in thoracic oncology].
    Rouviere D; Bousquet E; Pons E; Milia JD; Guibert N; Mazieres J
    Rev Mal Respir; 2015 Oct; 32(8):867-76. PubMed ID: 26076869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.